Potential of block copolymer- and immuno-conjugates for tumor-targeted delivery of Bowman-Birk soybean proteinase inhibitor

J Control Release. 2001 Jul 6;74(1-3):303-8. doi: 10.1016/s0168-3659(01)00337-6.

Abstract

The present work reports the effect of conjugation of the anticarcinogenic and antitumor soybean Bowman-Birk protease inhibitor (BBI) with amphiphilic block copolymer of ethylene oxide and propylene oxide (PEO-PPO) as well as with monoclonal antibody via clinical dextran (D) on tumor-targeted delivery of BBI.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Monoclonal / administration & dosage
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / pharmacokinetics
  • Antineoplastic Agents / pharmacology*
  • Caco-2 Cells
  • Dextrans
  • Drug Carriers
  • Drug Delivery Systems
  • Epoxy Compounds
  • Ethylene Oxide
  • Fluorescent Antibody Technique
  • Humans
  • Immunoconjugates / administration & dosage*
  • Immunoconjugates / pharmacokinetics
  • Immunoconjugates / pharmacology*
  • Immunohistochemistry
  • Mice
  • Polymers
  • Tissue Distribution
  • Trypsin Inhibitor, Bowman-Birk Soybean / administration & dosage*
  • Trypsin Inhibitor, Bowman-Birk Soybean / pharmacokinetics
  • Trypsin Inhibitor, Bowman-Birk Soybean / pharmacology*

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Dextrans
  • Drug Carriers
  • Epoxy Compounds
  • Immunoconjugates
  • Polymers
  • Trypsin Inhibitor, Bowman-Birk Soybean
  • Ethylene Oxide
  • propylene oxide